Abstract
Captopril (CAP) was the first commercially available angiotensine-converting enzyme (ACE) inhibitor. In the anti-hypertensive therapy is considered the selected drug has to be therapeutically effective together with reduced toxicity. CAP is an antihypertensive drug currently being administered in tablet form. In order to investigate the possible interactions between CAP and excipients in tablets formulations, differential scanning calorimetry (DSC) and thermogravimetric (TG) analysis completed by X-ray powder diffraction (XRPD) and Fourier transform infrared spectroscopy (FTIR) were used for compatibility studies. A possible drug-excipient interaction was observed with magnesium stearate by DSC technique.
Similar content being viewed by others
References
K. J. Lee, A. Khang, J. J. Delfino, T. G. West, D. Chetty, D. C. Monkhouse and J. Yo, Drug. Dev. Ind. Pharm., 29 (2003) 967.
R. S. Matharu and N. M. Sanghavi, Drug. Dev. Ind. Pharm., 18 (1992) 1567.
M. A. Khan, S. R. Sastry, S. R. Vaithiyalingam, V. Agarwal, S. Nazzal and I. K. Reddy, Int. J. Pharm., 193 (2000) 147.
K. Jackson, D. Young and S. Pant, Research Focus., 3 (2000) 336.
P. Mura, M. T. Faucci, A. Manderioli and L. Ceccarelli, J. Pharm. Biomed. Anal., 18 (1998) 151.
P. Mura, M. T. Faucci, A. Manderioli, S. Furlanetto and S. Pinzautti, Drug. Dev. Ind. Pharm., 24 (1992) 1567.
R. K. Verma and S. Grag, J. Pharm. Biomed. Anal., 35 (2004) 449.
G. Bruni, L. Amici, V. Berbenni, A. Marini and A. Orlandi, J. Therm. Anal. Cal., 68 (2002) 561.
A. Gombás, P. Szabó-Révész, M. Kata, G. Regdon and I. Erõs, J. Therm. Anal. Cal., 68 (2002) 503.
P. Mura, G. P. Bettinetti, M. T. Faucci, A. Manderioli and P.L. Parrini, Thermochim. Acta, 321 (1998) 59.
Y. E. Zang and J. B. Schwartz, Drug. Dev. Ind. Pharm., 26 (2000) 765.
A. H. Kibbe, In: Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London 2000, p. 306.
L. Lachman, H. A. Lieberman and J. L. Kaning, Teoria e Prática na Indústria Farmacêutica, Fundação Calouste, Lisboa 2001, p.1517.
J. J. Gomes-Pinho, J. R. Matos and L. P. Mercuri, An. Assoc. Bras. Quim., 47 (1998) 307.
G. P. Bettinetti, P. Mura and A. Liguori, Farmaco., 43 (1988) 343.
G. Pyramides, J. W. Robinson and S. W. Zito, J. Pharm. Biomed. Anal., 13 (1995) 103.
G. G. G. Oliveira, H. G. Ferrazi and J. S. R. Matos, J. Therm. Anal. Cal., 79 (2005) 267.
S. A. Botha and A. P. Lotter, Drug. Dev. Ind. Pharm., 15 (1989) 426.
K. D. Ertel and J. T. Carstensen, Int. J. Pharm., 42 (1988) 171.
A. P. Lotter, C. E. P. Malan and M. Villiers, Drug. Dev. Ind. Pharm., 23 (1997) 537.
Y. Huang, Y. Cheng, K. Alexander and D. Dollimore, Thermochim. Acta, 367 (2001) 43.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stulzer, H.K., Rodrigues, P.O., Cardoso, T.M. et al. Compatibility studies between captopril and pharmaceutical excipients used in tablets formulations. J Therm Anal Calorim 91, 323–328 (2008). https://doi.org/10.1007/s10973-006-7935-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10973-006-7935-1